The primary endpoint ( PEP ) and its component , hospitalisation for worsening HF , were more frequent in COPD patients ( HRs f , 1.22 [ p = 0.006 ] ; and 1.34 [ p < 0.001 ] ) respectively , but relative risk was reduced similarly by ivabradine in both COPD ( 14 % , and 17 % ) and non-COPD ( 18 % and 27 % ) patients ( p interaction = 0.82 , and 0.53 , respectively ) .